Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers

NCT01505907 is registered in ClinicalTrials.gov with CeNeRx BioPharma Inc. as lead sponsor.

NCT NCT01505907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01505907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers
Lead sponsor
CeNeRx BioPharma Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2012
Completion date
December 31, 2014
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy